Vivas logo

Pharmacology consulting
from strategy to execution.

A senior partner for biotech and pharma teams developing new medicines, turning early-stage science into programs that move forward.

Get in touch

Vivas is a senior pharmacology partner for teams developing new medicines. We work across the full arc of a program: from scientific and portfolio strategy, to the hands-on execution of preclinical pharmacology, to the scientific writing that moves a program forward. Every engagement is grounded in 20 years of in vivo pharmacology and translational science.

What Vivas does

Three connected services; pharmacology support from strategy to execution.

Strategy

From strategy: clarity on what to develop, and how to develop it.

  • Scientific, operational, and business strategy at the program and portfolio level
  • Go/no-go decision frameworks that keep programs honest
  • First-in-human and translational strategy, including PAD vs. MABEL dose approaches
  • Biomarker strategy to connect mechanism to clinical readout

Project Management

…to execution: preclinical programs planned, run, and delivered.

  • Planning, scoping, and running preclinical pharmacology programs
  • CRO identification, selection, and oversight
  • Design, analysis, and reporting of in vivo pharmacology studies
  • Milestone and budget delivery in fast-moving environments

Medical & Scientific Writing

Scientific communication, scoped to exactly what your program needs.

  • Study reports and regulatory documents
  • Scientific presentations and slide decks
  • Manuscripts to help you broaden the published literature base around your program

Need a format not listed here? Let's scope it together.

About

Adam Drake Founder

Adam founded Vivas to give emerging biotech and pharma teams direct access to senior pharmacology expertise. He brings 20 years across academia and industry; a decade at MIT's Koch Institute and Center for Cancer Research, followed by 10+ years in industry leadership. He has headed in vivo pharmacology and bioassay development at IGI/Ichnos Sciences (Senior Director, Switzerland), led in vivo pharmacology at FORMA Therapeutics, and directed humanized mouse research at New Paradigm Biosciences. His work spans immunology, oncology, immune-oncology, hematology, and metabolic disease, from basic research through early clinical development, with deep expertise in in vivo pharmacology, translational science, DMPK and human dose projection, biomarker strategy, CRO management, and IND filing. He is equally at home across large and small molecules, with particular familiarity developing complex bispecific and multispecific biologics. Adam holds an MA, MSci, and PhD in Biochemistry from the University of Cambridge.

Track record

A selection of programs Adam has contributed to and led portions of, working alongside the teams that brought them forward.

ISB 2001

Trispecific multiple-myeloma antibody, licensed to AbbVie (dose-finding ongoing).

Adam made key contributions to a novel first-in-human strategy allowing PAD dosing in the absence of a tox species.

ISB 880

IL1RAP blocking antibody, licensed to Almirall for hidradenitis suppurativa.

ISB 830

OX40 antagonist, licensed to Astria (STAR-0310 program) for atopic dermatitis.

Etavopivat

Sickle cell disease IND; early clinical work that contributed to Novo Nordisk's acquisition of FORMA Therapeutics.

Let's talk

Have a program you'd like a senior pharmacology view on? Start with an introductory conversation.